Interfering with chemokines and chemokine receptors as potential new therapeutic strategies

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 3, 2008, Pages 309-325

  D'Elios, Mario Milco ^a   Del Prete, Gianfranco ^a   Amedei, Amedeo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

AIDS; Asthma; Atherosclerosis; Cancer; Chemokine receptor; Chemokines; Diabetes; HIV; Infectious diseases; Multiple sderosis; Psoriasis; Rheumatoid arthritis; Sarcoidosis; Therapy; Transplantation

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 4 [3 [4 (3,4 DICHLOROBENZYL) 2 MORPHOLINYLMETHYL]UREIDOMETHYL]BENZAMIDE; APLAVIROC; BINDING PROTEIN; C 4462; C 6448; CANCER VACCINE; CCX 105; CCX 469; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CP 481715; CYCLOSPORIN; DPC 168; INTERLEUKIN 8 ANTIBODY; LIGAND; MARAVIROC; MLN 1202; MLN 3897; MONOCLONAL ANTIBODY; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PLACEBO; PLERIXAFOR; SB 656933; T 487; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ALLERGIC DISEASE; ASTHMA; ATHEROSCLEROSIS; CHEMOTAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; GRAFT REJECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER TOXICITY; MONOTHERAPY; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE;

EID: 42549172436     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.3.309     Document Type: Review

References (140)

1. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Ann Rev Immunol 1997;15:675-705
2. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-7
3. Baggiolini M. Chemokines in pathology and medicine. J Intern Med 2001;250:91-104
4. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001;2:123-8
5. Legler DF, Loetscher M, Roos RS, et al. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998;187:655-60
6. Ono SJ, Nakamura T, Miyazaki D, et al. Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol 2003;111:1185-99
7. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Ann Rev Immunol 2000;18:593-620
8. Romagnani S. Regulation of the T cell response. Clin Exp Allergy 2006;36:1357-66
9. D'Elios MM, Del Prete G. Th1/Th2 cytokine network In: Martino G, Adorini L, editors, Topics in Neuroscience. Springer, Berlin 1999;68-82
10. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8:639-46
11. Le Y, Zhou Y, Iribarren P, Wang J. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 2004;1:95-104
12. Ribeiro S, Horuk R. The clinical potential of chemokine receptor antagonists. Pharmacol Ther 2005;107:44-58
13. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-50
14. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection Cell 1996;86:367-77
15. D'Elios MM, Josien R, Manghetti M, et al. Predominant Th1 cell infiltration in acute rejection episodes of human kidney grafts. Kidney Int 1997;51:1876-84
16. Gao W, Topham PS, King JA, et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000;105:35-44
17. Benagiano M, Azzurri A, Ciervo A, et al. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci USA 2003;100:6658-63
18. Yla-Herttuala S, Lipton BA, Rosenfeld ME, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991;88:5252-556
19. Braunersreuther V, Zernecke A, Arnaud C, et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007;27:373-9
20. D'Elios MM, Manghetti M, De Carli M, et al. Th1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol 1997;158:962-7
21. Mach F, Sauty A, Iarossi AS, et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999;104:1041-50
22. Arenberg DA, Kunkel SL, Polverini PJ, et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996;184:981-92
23. Cabioglu N, Yazici MS, Arun B, et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 2005;11:5686-93
24. Muller A, Sonkoly E, Eulert C, et al. Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int J Cancer 2006;118:2147-57
25. Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006;203:2201-13
26. Kim J, Takeuchi H, Lam ST, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005;23:2744-53
27. Mullins IM, Slingluff CL, Lee JK, et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004;64:7697-701
28. Schering Aktiengesellschaft. Non-peptide CCR1 receptor antagonist in combination with cyclosporin a for the treatment of heart transplant rejection. WO0209762 (2002)
29. Schering Aktiengesellschaft. Non-peptide CCR1 receptor antagonist for the treatment of progressive renal fibrosis. WO03013656 (2003)
30. Frederick MJ, Henderson Y, Xu X, et al. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 2000;156:1937-50
31. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106:2018-25
32. Liang M, Mallari C, Rosser M, et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 2000;275:19000-8
33. Horuk R, Clayberger C, Krensky AM, et al. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem 2001;276:4199-204
34. Zipp F, Hartung HP, Hillert J, et al. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 2006;67:1880-3
35. Anders HJ, Vielhauer V, Frink M, et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 2002;109:251-9
36. Naya A, Ishikawa M, Matsuda K, et al. Structure-activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists. Bioorg Med Chem 2003;11:875-84
37. Millennium Pharmaceuticals. CCR1 antagonist for the treatment of I.A. demyelinating inflammatory disease. US2005288319 (2005)
38. Brown MF, Avery M, Brissette WH, et al. Novel CCR1 antagonists with improved metabolic stability. Bioorg Med Chem Lett 2004;14:2175-9
39. R&D at Millennium: Available from: http://www.mlnm.com/rd/ inflammation/candidates/ccr1.asp [last accessed February 28, 2008]
40. Pfizer Products, Inc. Use of piperazine derivatives as CCR1 antagonist. WO2004039376 (2004)
41. Gladue RP, Tylaska LA, Brissette WH, et al. CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J Biol Chem 2003;278:40473-80
42. Haringman JJ, Kraan MC, Smeets TJ, et al. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:715-21
43. Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists. WO1998004554 (1998)
44. Naya A, Sagara Y, Ohwaki K, et al. Design, synthesis, and discovery of a novel CCR1 antagonist. J Med Chem 2001;44:1429-35
45. Chemocentryx, Inc. 1-Aryl-4-substituted piperazines derivatives for use as CCR1 antagonists for treatment of inflammation and immune disorders. WO03105853 (2003)
46. Ribeiro S, Horuk R. The clinical potential of chemokine receptor antagonists. Pharmacol Ther 2005;107:44-58
47. Pfizer. Tropane derivatives as CCR5 modulators. US2004014742 (2004)
48. Schering Corporation. Piperazine derivatives useful as CCR5 antagonist. WO0066558 (2000)
49. Ono Pharmaceuticals, Habashita, et al. Chemokine receptor antagonist and medical use thereof. WO2005023771 (2005)
50. Maeda K, Nakata H, Koh Y, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 2004;78:8654-62
51. Lalezari J, Thompson M, Kumar P, et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 2005;19:1443-8
52. Takeda Chemical Industries Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative. WO9932100 (1999)
53. Incyte Corporation. 3-Aminopyrrolidine derivatives as modulators of chemokine receptors. WO2004050024 (2004)
54. Incyte website: Available from: http://www.incyte.com [last accessed February 28, 2008]
55. Davidson M. MLN 1202, a novel 2007 CCR2 antagonist decreases C reactive-protein in patients at risk for atherosclerotic cardiovascular disease in a double blind placebo controlled study. Proceedings of the American Heart Association Meeting November 4-7; Orlando, FL; 2007
56. Glaxo Group Ltd. Morpholinylmethylureas CCR-3 receptor antagonists. WO03097618 (2003)
57. Glaxo Group Ltd. Morpholine derivatives with a substituted acetamide group in the 2-position for use as CCR-3 antagonists for treatment of inflammatory disease. WO03082294 (2003)
58. Du Pont Pharmaceutical Co. Heterocyclic piperidines as modulators of chemokine receptor activity. WO0035877 (2000)
59. De Lucca GV, Kim UT, Vargo BJ, et al. Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency. J Med Chem 2005;48:2194-211
60. Hodgson S, Charlton S, Warne P. Chemokines and drug discovery. Highlights from the Society for Medicines Research Meeting United Kingdom; 2004
61. Chemocentryx. Heterocyclic compounds and methods for modulating CXCR3 function. WO0116114 (2001)
62. Braddock M. Advances in anti-inflammatory therapeutics. Expert Opin Investig Drugs 2007;16:257-61
63. Smithkline Beecham Corporation. IL-8 receptor antagonists. WO1998034929 (1998)
64. Smithkline Beecham Corporation. IL-8 receptor antagonists. WO2004039775 (2004)
65. Salmon M, Carpenter DC, Dehaas CJ, et al. Inhibition of LPS-induced neutrophil recruitment in the lungs correlates with modulation of neutrophil CD11b expression using the selective CXCR2 receptor antagonist SB-656933. Eur Resp J 2004;24(Suppl. 48):218
66. Carpenter DC, Rumsey WL, Busch-Petersen J, et al. The selective CXCR2 receptor antagonist SB-656933 inhibits CXCL1-induced neutrophil CD11b expression in human whole blood. Eur Resp J 2004;24(Suppl. 48):218
67. Anormed, Inc. Methods to mobilize progenitors/stem cells. WO2005000333 (2005)
68. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1253-62
69. Genzyme website: Available from: http://www.genzyme.com [last accessed February 28, 2008]
70. Chemocentryx. Arylsulfonamides. WO2004046092 (2004)
71. Chemocentryx website: Available from: http://www.chemocentryx.com [last accessed February 28, 2008]
72. Zeneca Ltd. MCP-1 analogs. WO1999005279 (1999)
73. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-1pr mouse model. J Exp Med 1997;186:131-7
74. Dana Farber Cancer Institute. Chemokine N-terminal deletion mutations. WO1996038559 (1996)
75. Wada T, Furuichi K, Sakai N, et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol 2004;15:940-8
76. Glaxo Group Ltd Wells. Rantes peptide and fragments and compositions comprising it for treatment of inflammation. WO1996017935 (1996)
77. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002;2:106-15
78. Gryphon Therapeutics. Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use. WO2002004015 (2002)
79. Simmons G, Clapham PR, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-9
80. Gryphon Therapeutics. Synthetic chemokines, methods of manufacture, and use. WO2005097168 (2005)
81. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaquas through inhibition of CCR5. Science 2004;306:485-7
82. Serono. Chemokine mutants in the treatment of multiple sclerosis. WO2002028419 (2002)
83. Johnson Z, Kasco-Vilbois MH, Herren S, et al. Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol 2004;173:5776-85.
84. Kennedy KJ, Strieter RM, Kunkel SL, et al. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1. J Neuroimmunol 1998;92:98-108
85. Millennium Pharmaceuticals. Treating graft rejection with CXCR3 inhibitors. WO2001078708 (2001)
86. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000;192:1515-20
87. Abgenix. Methods for treating chronic obstrutive pulmonary disease (COPD). WO2003080117 (2003)
88. Yes Biotech Laboratories. Topical treatment of psoriasis using neutralizing antibodies to IL-8. WO1998058671 (1998)
89. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004;126:926-34
90. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73
91. Bizzarri C, Beccari AR, Bertini R, et al. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 2006;112:139-49
92. Millennium Pharmaceuticals. Humanized anti-CCR2 antibodies and methods of use. WO2005060368 (2005)
93. Millennium: Investor overview: Available from: http://investor.millennium.com [last accessed February 28, 2008]
94. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990:343:341-6
95. Seckinger P, Isaaz S, Dayer JM. A human inhibitor of tumor necrosis factor alpha. J Exp Med 1988;167:1511-6
96. Xiang Y, Moss B. IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins. Proc Natl Acad Sci USA 1999;96:11537-42
97. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000;81:2341-64
98. Liu L, Dai E, Miller L, et al. Viral chemokine-binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models. Transplantation 2004;77:1652-60
99. Kocáková P, Sláviková M, Hajnická V, et al. Effect of fast protein liquid chromatography fractionated salivary gland extracts from different ixodid tick species on interleukin-8 binding to its cell receptors. Folia Parasitol (Praha) 2003;50:79-84
100. Fushimi T, O'Connor TP, Crystal RG. Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Res 2006;66:3513-22
101. Guo J, Wang B, Zhang M, et al. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 2002;9:793-803
102. Okada N, Gao JQ, Sasaki A, et al. Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host's immune system: implications for chemokine-based cancer immunotherapy. Biochem Biophys Res Commun 2004;317:68-76
103. Biragyn A, Belyakov IM, Chow YH, et al. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 2002;100:1153-9
104. Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res 2004;10:7529-39
105. Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001;194:847-53
106. Vlad G, Cortesini R, Suciu-Foca N. License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J Immunol 2005;174:5907-14
107. Trifilo MJ, Lane TE. The CC chemokine ligand 3 regulates CD11c+CD11b+CD8 alpha-dendritic cell maturation and activation following viral infection of the central nervous system: implications for a role in T cell activation. Virology 2004;327:8-15
108. Nakashima E, Oya A, Kubota Y, et al. A candidate for cancer gene therapy: MIP-1 alpha gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm Res 1996;13:1896-901
109. Bystry RS, Aluvihare V, Welch KA, et al. B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2001;2:1126-32
110. Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006;25:315-22
111. D'Ambrosio D, Sinigaglia F, Adorini L. Special attractions for suppressor T cells. Trends Immunol 2003;24:122-6
112. Penna G, Vulcano M, Roncari A, et al. Cutting edge: differential chemokine production by myeloid and plasmacytoid dendritic cells. J Immunol 2002;169:6673-6
113. George TC, Bilsborough J, Viney JL, Norment AM. High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro. Eur J Immunol 2003;33:502-11
114. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med 2000;343:338-44
115. Rissoan MC, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999;283:1183-6
116. Delamarre L, Holcombe H, Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC dass II molecules is differentially regulated during dendritic cell maturation. J Exp Med 2003;198:111-22
117. Heath WR, Belz GT, Behrens GM, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004;199:9-26
118. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002;2:106-15
119. Zaliauskiene L, Kang S, Sparks K, et al. Enhancement of MHC class II-restricted responses by receptor-mediated uptake of peptide antigens. J Immunol 2002;169:2337-45
120. Biragyn A, Tani K, Grimm MC, et al. Genetic fission of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999;17:253-8
121. Yang D, Chertov O, Bykovskaia SN, et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999;286:525-8
122. Biragyn A, Surenhu M, Yang D, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001;167:6644-53
123. Schiavo R, Baatar D, Olkhanud P, et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T cell responses. Blood 2006;107:4597-605
124. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002;298:1025-9
125. Government of The USA. Viral chemokine-tumor antigen fusion proteins. WO2002022687 (2002)
126. University of Southern California. Compositions and methods for cancer immunotherapy. WO2004074437 (2004)
127. Instituto Cientifico Y Tecnologico De Navarra. Combined used of chemokine IP-10 and Interleukin 12 in the preparation of compositions for the treatment of malignant tumors. WO2001062274 (2001)
128. Medigene Aktiengesellchaft. Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases. WO2003039444 (2003)
129. Amedei A, Cappon A, De Bernard M, et al. Use of the neutrophil activating protein of Helicobacter pylori (HP-NAP) and/or its portions as adjuvants for the development of T helper type 1 (Th1) immune responses. WO2007039451 (2007)
130. Schering Corporation. Chemokine as adjuvants of immune response. WO2002058723 (2002)
131. Cleveland Clinic Foundation. CCR ligands for stem cell homing. WO2006002152 (2006)
132. Topol EJ, Gusto V. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-14
133. Penn MS, Francis GS, Ellis SG, et al. Autologous cell transplantation for the treatment of damaged myocardium. Prog Cardiovasc Dis 2002;45:21-32
134. Jain M, Dersimonian H, Brenner DA, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001;103:1920-7
135. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-5
136. Jackson KA, Majka SM, Wang H, et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001;107:1395-402
137. Quaini F, Urbanek K, Beltrami AP, et al. Chimerism of the transplanted heart. N Engl J Med 2002;346:5-15
138. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430-46
139. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001;98:10344-9
140. Yoshimura T, Matsushima K, Tanaka S, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 1987;84:9233-7